An Evaluation of the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia

Schizophrenia Clinical Trial

Official title:

Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABT-925 in Subjects With Acute Exacerbation of Schizophrenia

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00412620
• Other study ID #: M06-816
• Status: Terminated
• Phase: Phase 2
• First received: December 14, 2006
• Last updated: April 25, 2011
• Start date: December 2006
• Est. completion date: October 2007

Study information

• Verified date: September 2010
• Source: Abbott
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationMexico: Ministry of HealthArgentina: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to explore the safety and efficacy of ABT-925 involving patients who meet the DSM-IV-TR (Diagnostic and Statistical Manual of Medical Disorders, Fourth Edition Text Revision) criteria for an acute exacerbation of schizophrenia or schizoaffective disorder.

Description:

To explore the safety and efficacy of ABT-925 treatment at three different doses for 6 weeks compared with placebo in subjects with a diagnosis of acute exacerbation of schizophrenia or schizoaffective disorder according to DSM-IV-TR criteria (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision).

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 156
• Est. completion date: October 2007
• Est. primary completion date: October 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• The subject has a current primary diagnosis of schizophrenia or schizoaffective disorder; specifically, an acute exacerbation with prominent "active phase" symptoms, as described in Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision criteria (and confirmed by the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision). Subjects with schizophrenia may belong to any of the following subtypes: paranoid, disorganized, catatonic, or undifferentiated.

• The subject has a The Positive and Negative Syndrome Scale total score of greater than or equal to 60.

• The subject has a score of greater than 4 ("moderate") on at least 2 out of the following 5 The Positive and Negative Syndrome Scale positive symptoms: delusions, conceptual disorganization, hallucinatory behavior, grandiosity, suspiciousness/persecution.

• The subject is between 18 and 65 years old inclusive at the time of randomization.

• The subject has a reliable caregiver (if applicable) or an identified responsible (e.g., family member, social worker, nurse) who will support him/her to ensure compliance with treatment and outpatient visits. In addition, the subject must have an adequate place of residence.

• The subject agrees to be hospitalized for the duration of the Taper off/Washout Period and at least the first fourteen days of the Double-blind Period.

Exclusion Criteria:

• The subject has a body mass index greater than 35.

• The subject has any condition that in the opinion of the investigator is likely to place him/her at an unacceptable safety risk by entering the study or by treatment with ABT-925.

• The subject has a diagnosis of one or more of the following conditions: another primary Axis I disorder, including schizophreniform disorder, bipolar disorder or major depressive disorder; comorbid Axis II diagnoses, including borderline personality disorder and mental retardation. (Note: a diagnosis of depression not otherwise specified is acceptable for inclusion into the study).

• The subject has a diagnosis of substance or alcohol disorder (abuse/dependence according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision criteria), excluding nicotine, within one (1) month prior to the beginning of the Screening Period, or in the opinion of the investigator, a disorder that will interfere with the conduct of the study.

• The subject has a history of substance-induced psychotic disorder in the previous 6 months.

• The subject has evidence suggestive of treatment-resistant schizophrenia (i.e., lack of significant clinical improvement despite adequate courses and doses of at least two different antipsychotic medications during the previous 2 years; or adequate use of clozapine indicated for treatment-resistant schizophrenia).

• The subject has serious violent, homicidal or suicidal ideation in the opinion of the investigator.

• The subject has a screening QT interval corrected by Bazett formula interval of greater than 430 msec if male and greater than 450 msec if female.

• The subject's Liver Function Tests (Aspartate aminotransferases, Alanine aminotransferase or total bilirubin levels) are not within normal limits at screening.

• The subject has a diagnosis, history, or a positive serological result suggestive of liver disease including but not limited to hepatitis and Gilbert's Syndrome.

• The subject has received any of the following treatments within the time periods described: mood stabilizers or antidepressants during the 30 days prior to Screening; electroconvulsive therapy during the 3 months prior to Screening; clozapine during 60 days prior to Screening.

• The subject is currently receiving treatment with oral psychotropic medications or has received depot neuroleptics within one inter-injection interval.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Drug:
• ABT-925

• Placebo

Locations

Country	Name	City	State
Argentina	Site Reference ID/Investigator# 5227	Buenos Aires
Argentina	Site Reference ID/Investigator# 5226	Cordoba
Argentina	Site Reference ID/Investigator# 5224	La Plata
Mexico	Site Reference ID/Investigator# 4305	Guadalajara
Mexico	Site Reference ID/Investigator# 4303	Mexico City
Mexico	Site Reference ID/Investigator# 4304	Mexico City
Mexico	Site Reference ID/Investigator# 4298	Monterrey
United States	Site Reference ID/Investigator# 5188	Anaheim	California
United States	Site Reference ID/Investigator# 4168	Atlanta	Georgia
United States	Site Reference ID/Investigator# 4176	Austin	Texas
United States	Site Reference ID/Investigator# 4567	Austin	Texas
United States	Site Reference ID/Investigator# 4371	Bellaire	Texas
United States	Site Reference ID/Investigator# 4539	Cerritos	California
United States	Site Reference ID/Investigator# 4175	Garden Grove	California
United States	Site Reference ID/Investigator# 4177	North Miami	Florida
United States	Site Reference ID/Investigator# 4553	Pico Rivera	California
United States	Site Reference ID/Investigator# 4173	San Diego	California
United States	Site Reference ID/Investigator# 4565	Upland	California

Sponsors (1)

Lead Sponsor	Collaborator
Abbott

Countries where clinical trial is conducted

United States,  Argentina,  Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Positive and Negative Syndrome Scale	The PANSS (The Positive and Negative Syndrome Scale) assesses the severity of symptoms of schizophrenia over the preceding seven days. The PANSS items are divided into positive, negative, and general psychopathology factors. The PANSS total score is the score of all 30 PANSS items taken together.	Assessed at screening and weekly from baseline through week 42/premature discontinuation	No
Secondary	Brief Psychiatric Rating Scale	Subscale of PANSS (The Positive and Negative Syndrome Scale)	Assessed at screening and weekly from baseline through week 42/premature discontinuation	No
Secondary	Clinical Global Impression Severity score	Assesses the overall, absolute degree of illness at any point in time (refer to the degree of illness at the time of the visit and during the week prior to the visit).	Assessed at screening and weekly from baseline through week 42/premature discontinuation	No
Secondary	Calgary Depression Scale for Schizophrenia Total score	The CDSS (Calgary Depression Scale for Schizophrenia Total score) consists of items designed to assess the severity of symptoms of depression in the presence of schizophrenia such as depressed mood, hopelessness, guilt, and insomnia.	Assessed at screening and weekly from baseline through week 42/premature discontinuation	No
Secondary	Negative Symptom Assessment	The NSA (Negative Symptom Assessment) is a 16-item instrument plus a one-item global rating designed to measure specific negative symptoms in schizophrenia	Assessed at screening and weekly from baseline through week 42/premature discontinuation	No